New antibody treatment shows potential against dengue virus
新型抗體療法在對抗登革熱病毒方面展現潛力
更新於: 2026年7月21日 上午04:00
Dengue fever, a mosquito-borne disease affecting millions in tropical regions, has long been a medical challenge.
登革熱是一種透過蚊子傳播的疾病，影響著熱帶地區數百萬人，長期以來一直是一項醫學挑戰。
Historically, patients diagnosed with the virus received only supportive care, as there have been no FDA-approved antiviral treatments.
從歷史上看，被診斷出感染該病毒的患者僅能接受支持性治療，因為目前還沒有獲得FDA核准的抗病毒療法。
However, science is now shifting from generalized supportive care toward a precise, targeted approach using engineered antibodies.
然而，科學界現在正從通用的支持性照護，轉向利用工程抗體進行精準、標靶性的治療。
A major hurdle in dengue treatment has been the risk of 'enhancement,' where the immune system reacts poorly to a secondary infection.
登革熱治療的主要障礙之一是「增強作用」(enhancement)的風險，即免疫系統對二次感染產生不良反應。
Researchers are testing monoclonal antibodies like AV-1, which aim to reduce symptoms and speed up recovery.
研究人員正在測試如AV-1等單株抗體，旨在減輕症狀並加速恢復。
Simultaneously, scientists are developing bispecific antibodies that not only target the virus but also block the 'cytokine storm'—the dangerous, overactive inflammatory response that causes organ damage.
同時，科學家正在開發雙特異性抗體，這些抗體不僅能標靶病毒，還能阻斷「細胞激素風暴」(cytokine storm)——即導致器官受損的危險性過度發炎反應。
Furthermore, broadly neutralizing antibodies (bNabs) are being identified that can tackle all four strains of the dengue virus at once.
此外，科學家已識別出廣效中和抗體(bNabs)，能同時對抗四種登革熱病毒株。
By modifying these antibodies for longer-lasting effects and improved safety, scientists are paving the way for a future where dengue can be treated with precision, potentially offering hope against other related viruses like Zika.
透過改造這些抗體以延長藥效並提高安全性，科學家正為未來能以精準方式治療登革熱鋪平道路，並可能為對抗其他相關病毒帶來希望。
